Need professional-grade analysis? Visit stockanalysis.com
$46.21B
N/A
2,903
N/A
Shanghai Junshi Biosciences Co Ltd (688180) trades on SHG in CNY. The company is classified in the Healthcare sector under the Biotechnology industry. The stock currently trades at CNY45.04, up 1.49% from the previous close.
Over the past year, 688180 has traded between a low of CNY28.43 and a high of CNY48.80. The stock has gained 49.4% over this period. It is currently 7.7% below its 52-week high.
Shanghai Junshi Biosciences Co Ltd has a market capitalization of $46.21B.
Shanghai Junshi Biosciences Co., Ltd., a biopharmaceutical company, engages in the discovery, development, and commercialization of various drugs in China. The company's product pipelines include Tifcemalimab, an anti- B and T lymphocyte attenuator mAB which is in phase III clinical trial to treat lung cancer and lymphocyte; Roconkibart, an anti-interleukin-17A monoclonal antibody which is in phase III clinical trial to treat psoriatic and spondylitis; JS001sc, a subcutaneous injection which is in phase III clinical trial for the treatment of tumors; JS105, an oral small molecule inhibitor targeting PI3K-a which is in phase III clinical trial to treat gynecological tumors; and JS107, an antibody-drug conjugate which is in phase III clinical trial for the treatment of gastrointestinal cancer. It also develops JS212, JS213, JS207, JS203, JS125, JS214, and JS214 which is in phase I/II clinical trial for the treatment of tumors; JS111, a small molecule inhibitor targeting which is in phase I/II clinical trial to treat NSCLC; JS110, a small molecule inhibitor of the nuclear export protein XPO1 which is in phase I/II clinical trial to treat endometrial cancer; JS007, a recombinant humanized anti-Cytotoxic T lymphocyte associated antigen-4 monoclonal antibody which is in phase I/II clinical trial to treat lung cancer and melanoma; and JT002, A small nucleic acid immunomodulator which is in phase I/II clinical trial for the treatment of seasonal allergic rhinitis. In addition, the company offers TUOYI/LOQTORZI/ZYTORVI for tumors; JUNMAIKANG for the treatment of rheumatoid arthritis, ankylosing spondylitis, psoriasis, Crohn's disease, uveitis, polyarticular juvenile idiopathic arthritis, pediatric plaque psoriasis, and pediatric Crohn's disease; VV116/JT001, an oral nucleoside analog drug; and JUNSHIDA to treat hyperlipidemia. The company was founded in 2012 and is headquartered in Shanghai, People's Republic of China.
Side-by-side comparison against top Healthcare peers.